# EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study

> **NCT07281105** · PHASE2 · COMPLETED · sponsor: **Evergreen Therapeutics, Inc.** · enrollment: 131 (actual)

## Conditions studied

- Neuropsychiatric Systemic Lupus Erythematosus
- Systemic Lupus Erythematosus (SLE)
- Cognitive Impairment

## Interventions

- **DRUG:** Placebo
- **DRUG:** EG-501

## Key facts

- **NCT ID:** NCT07281105
- **Lead sponsor:** Evergreen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-08-12
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281105, "EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07281105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*